Tenax Therapeutics develops advanced therapies for serious cardiovascular and pulmonary conditions. Its lead programs target pulmonary hypertension in patients with heart failure with preserved ...
Net loss totaled $10.85 million for Q2 2025, compared to $3.6 million in Q2 2024. Operating expenses more than tripled in Q2 2025 versus Q2 2024, driven by higher R&D and G&A costs, including $4.6 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results